Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Eggermont

Showing results (1-10 of 139) with videos related to

Pageof 14
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 4, 2006
Putting Europe in the driving seatAlexander Eggermont
Molecular Oncology|April 29, 2009
An interview with Alexander EggermontJanet Fricker, Alexander Eggermont
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 25, 2012
Advances in immuno-oncology. ForewordAlexander Eggermont, Olivera Finn
European Journal of Cancer (Oxford, England : 1990)|November 29, 2015
How should we use anti-CTLA-4 antibodies?Aurélien Marabelle, Alexander Eggermont
Pigment Cell & Melanoma Research|March 24, 2009
Highlights from the perspectives in melanoma XII conferenceJohn M Kirkwood, Alexander Eggermont
Journal for Immunotherapy of Cancer|January 19, 2022
Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054Alexander Eggermont, Michal Kicinski, Stefan Suciu
Cancer Discovery|November 2, 2021
Precision Cancer Medicine: Large Studies Indicate Steady ProgressAlexander Eggermont, Birgit Geoerger, Giuseppe Curigliano
Oncoimmunology|March 5, 2016
Doubling the blockade for melanoma immunotherapyLorenzo Galluzzi, Alexander Eggermont, Guido Kroemer
The New England Journal of Medicine|April 4, 2019
Estimation of Distant Metastasis-free Survival in Trials of Adjuvant Therapy for MelanomaAlexander Eggermont, Stefan Suciu, Michal Kicinski
Oncoimmunology|May 6, 2015
Novel immune checkpoint blocker approved for the treatment of advanced melanomaLorenzo Galluzzi, Guido Kroemer, Alexander Eggermont
Pageof 14

Showing results (1-10 of 139) with videos related to

Sort By:
Pageof 14
European Journal of Cancer (Oxford, England : 1990)|March 4, 2006
Putting Europe in the driving seatAlexander Eggermont
Molecular Oncology|April 29, 2009
An interview with Alexander EggermontJanet Fricker, Alexander Eggermont
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 25, 2012
Advances in immuno-oncology. ForewordAlexander Eggermont, Olivera Finn
European Journal of Cancer (Oxford, England : 1990)|November 29, 2015
How should we use anti-CTLA-4 antibodies?Aurélien Marabelle, Alexander Eggermont
Pigment Cell & Melanoma Research|March 24, 2009
Highlights from the perspectives in melanoma XII conferenceJohn M Kirkwood, Alexander Eggermont
Journal for Immunotherapy of Cancer|January 19, 2022
Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054Alexander Eggermont, Michal Kicinski, Stefan Suciu
Cancer Discovery|November 2, 2021
Precision Cancer Medicine: Large Studies Indicate Steady ProgressAlexander Eggermont, Birgit Geoerger, Giuseppe Curigliano
Oncoimmunology|March 5, 2016
Doubling the blockade for melanoma immunotherapyLorenzo Galluzzi, Alexander Eggermont, Guido Kroemer
The New England Journal of Medicine|April 4, 2019
Estimation of Distant Metastasis-free Survival in Trials of Adjuvant Therapy for MelanomaAlexander Eggermont, Stefan Suciu, Michal Kicinski
Oncoimmunology|May 6, 2015
Novel immune checkpoint blocker approved for the treatment of advanced melanomaLorenzo Galluzzi, Guido Kroemer, Alexander Eggermont
Pageof 14